IP Library Granted Patent US 9,417,238
Granted Patent B2
US 9,417,238 · App. 14/080,700 · Granted Aug 16, 2016

Posterior segment drug delivery

Inventors: Cary J. Reich (Menlo Park, CA); Michael Barrett (Menlo Park, CA); Randolph E. Campbell (Menlo Park, CA); Kathleen C. Farinas (Menlo Park, CA)
Assignee: ForSight Vision4, Inc.
G01N33/558A61F9/0017A61K9/0048A61K9/0051A61K31/57A61K31/573Y10T29/49826
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,417,238
App. No.
14/080,700
Granted
Aug 16, 2016
Kind
B2
Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Claims (29)

1. A method of manufacturing a drug delivery therapeutic device implantable in an eye for prolonged treatment, the method comprising:

performing a non-destructive test on at least one porous structure, the non-destructive test selected from the group consisting of a gas flow rate test, a bubble point test, and a pressure decay test, wherein the at least one porous structure has a pre-formed shape, the at least one porous structure being part of a device having a refillable reservoir for containing at least one therapeutic agent with the at least one rigid porous structure coupled to the device in fluid communication with the reservoir, the rigid porous structure having a plurality of interconnecting channels and coupled to a distal portion of the reservoir;

obtaining from the non-destructive test at least one performance result for the at least one porous structure;

measuring a diffusion rate of a molecule according to passive, concentration-gradient driven molecular diffusion to obtain a measured diffusion rate, wherein the molecule diffuses through a porous structure, the porous structure being the at least one porous structure or at least another porous structure; and

correlating the at least one performance result of the at least one porous structure to the measured diffusion rate so as to form a correlation used to predict a measured diffusion rate of the molecule through at least a second porous structure.

2. The method as in claim 1 , further comprising:

performing the non-destructive test on the at least a second porous structure;

obtaining from the non-destructive test at least one performance result for the at least a second porous structure; and

predicting, based on the correlation, the measured diffusion rate of the molecule through the at least a second porous structure to obtain a predicted diffusion rate.

3. The method as in claim 2 , further comprising identifying the at least a second porous structure as suitable for assembly with the therapeutic device.

4. The method as in claim 2 , wherein the predicted diffusion rate corresponds to the diffusion rate of the through the at least one porous structure.

5. The method as in claim 2 , further comprising measuring a diffusion rate of a molecule through the at least a second porous structure to obtain a second measured diffusion rate and comparing the second measured diffusion rate to the predicted diffusion rate.

6. The method as in claim 5 , wherein measuring is performed prior to manufacturing the device with the second porous structure.

7. The method as in claim 5 , wherein measuring is performed after manufacturing the device with the second porous structure.

8. The method as in claim 2 , further comprising manufacturing the therapeutic device with the second porous structure without measuring a diffusion rate of a molecule through the at least a second porous structure and comparing to the predicted diffusion rate.

9. The method as in claim 1 , wherein the non-destructive test is performed on the at least one porous structure prior to assembling the at least one porous structure with the therapeutic device.

10. The method as in claim 1 , wherein the non-destructive test is performed on the at least one porous structure after at least partially assembling the at least one porous structure with the therapeutic device.

11. The method as in claim 10 , wherein the at least partially assembled therapeutic device includes the therapeutic agent contained in the reservoir.

12. The method as in claim 1 , wherein the non-destructive test is performed as a quality control inspection test upon receipt of the at least one porous structure from a manufacturer.

13. The method as in claim 1 , wherein the non-destructive test is performed as a quality control inspection test after final assembly of the therapeutic device.

14. The method as in claim 1 , wherein the non-destructive test is a test that does not involve drug release through the at least one porous structure.

15. A therapeutic device manufactured according to the method of claim 1 .

16. The method as in claim 1 , wherein the at least one porous structure is a rigid porous structure manufactured from sintered grains of material including metal, ceramic, glass or plastic.

17. The method as in claim 1 , wherein performing the non-destructive test comprises exposing the at least one porous structure to a gas.

18. A method of manufacturing a drug delivery device for prolonged treatment, the method comprising:

performing a non-destructive test on a first rigid porous structure, the non-destructive test selected from the group consisting of a gas flow rate test, a bubble point test, and a pressure decay test, the first rigid porous structure being part of a device having a refillable reservoir for containing at least one therapeutic agent with the first rigid porous structure coupled to the device in fluid communication with the reservoir, the first rigid porous structure having a plurality of interconnecting channels and coupled to a distal portion of the reservoir;

obtaining from the non-destructive test at least one performance result for the first rigid porous structure;

measuring a diffusion rate of a molecule according to passive, concentration-gradient driven molecular diffusion through the first rigid porous structure to obtain a measured diffusion rate; and

correlating the at least one performance result of the first rigid porous structure to the measured diffusion rate so as to form a correlation used to predict a measured diffusion rate of the molecule through at least a second porous structure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2013
From: REICH, CARY J.; BARRETT, MICHAEL; CAMPBELL, RANDOLPH E.; FARINAS, KATHLEEN COGAN
To: FORSIGHT VISION4, INC.
Reel/Frame 031813/0053 →
Continuity (8)
Continuation 13831695 · Mar 15, 2013
Continuation 12696678 · Jan 29, 2010
Provisional Application 61299282 · Jan 28, 2010
Provisional Application 61284832 · Dec 24, 2009
Provisional Application 61261717 · Nov 16, 2009
Provisional Application 61174887 · May 1, 2009
Provisional Application 61148375 · Jan 29, 2009
Related Publication 20140073714A1 · Mar 13, 2014